LETTER Open Access



Letter to the editor regarding "Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies"

Kate Magner^{1,2*}, Edward Clark^{1,3} and Swapnil Hiremath^{1,3}

To the Editor

On the heels of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial [1], Pan et al. [2] recently published a systematic review and meta-analysis of randomised controlled trials (RCTs) on the timing of renal replacement therapy for critically ill patients with acute kidney injury. They concluded that accelerated dialysis might benefit survival in a subgroup of surgical ICU patients, but not in a mixed ICU population. They also found that early initiation might have benefited patients who received CRRT, but not those who received other dialysis modalities. These results are based on subgroup analyses that included trials conducted solely in surgical ICU settings, or, in the second instance, where CRRT was the only type of dialysis used. The two trials conducted in surgical ICU settings, Sugahara et al. [3] and Zarbock et al. [4], included only 28 and 231 patients, respectively. In contrast, the STARRT-AKI trial, which was not factored into this analysis, included an overall population of 2927 patients of whom 965 were surgical patients. We determined that if these surgical patients had been included in the subgroup analysis, it would have resulted in a null effect for early initiation (OR 0.96, 95% CI 0.77, 1.21). Likewise, a subgroup analysis of trials involving only CRRT ignores that approximately 70% of the patients in the STARRT-AKI received CRRT as the initial RRT modality. Lastly, we note the omission of another potentially eligible trial, from Jamale et al. [5], which also reported no benefit with accelerated renal replacement therapy. On the whole, omitting the surgical or CRRT subgroups from the trials done in mixed ICU populations, particularly those from the STARRT-AKI trial, renders fallible the conclusion that accelerated renal replacement therapy initiation might reduce all-cause mortality in these settings. An individual patient-level meta-analysis might be more informative, but otherwise, the results of the largest trial, namely STARRT-AKI, are more robust than subgroup analyses that only considered patients from underpowered trials.

Acknowledgements

None.

Authors' contributions

KM drafted the letter, EC provided substantial revisions to the manuscript, and SH performed the calculations and provided substantial revisions to the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: kmagner@toh.ca

¹ Faculty of Medicine, The University of Ottawa, 451 Smyth Road, Ottawa, ON K1H8M5, Canada

Magner et al. Crit Care (2021) 25:96 Page 2 of 2

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

EC and SH were the Ottawa site investigators for the STARRT-AKI trial.

Author details

¹ Faculty of Medicine, The University of Ottawa, 451 Smyth Road, Ottawa, ON K1H8M5, Canada. ² The Ottawa Hospital, 501 Smyth Road, Ottawa, ON K1H8L6, Canada. ³ The Ottawa Hospital, Riverside Campus, 1967 Riverside Dr., Ottawa, ON K1H7W9, Canada.

Received: 23 February 2021 Accepted: 2 March 2021 Published online: 09 March 2021

References

 Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. 2020;383(3):240–51.

- Pan H-C, Chen Y-Y, Tsai I-J, Shiao C-C, Huang T-M, Chan C-K, et al. Accelerated versus standard initiation of renal replacement therapy for critically ill patients with acute kidney injury: a systematic review and meta-analysis of RCT studies. Crit Care. 2021;25(1):5.
- Sugahara S, Suzuki H. Early start on continuous hemodialysis therapy improves survival rate in patients with acute renal failure following coronary bypass surgery. Hemodial Int. 2004;8(4):320–5.
- Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically III patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315(20):2190–9.
- Jamale TE, Hase NK, Kulkarni M, Pradeep KJ, Keskar V, Jawale S, et al. Earlier-start versus usual-start dialysis in patients with communityacquired acute kidney injury: a randomized controlled trial. Am J Kidney Dis. 2013;62(6):1116–21.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\;$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

